Standard BioTools Inc.
LAB
$1.29
-$0.04-3.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -65.23% | 3.25% | -24.80% | -4.15% | 13.34% |
| Total Depreciation and Amortization | -1.06% | -25.72% | 2.21% | 27.92% | 464.70% |
| Total Amortization of Deferred Charges | 55.16% | 10.32% | -- | -183.64% | -148.25% |
| Total Other Non-Cash Items | 865.80% | 2,497.66% | -94.88% | -116.90% | -120.40% |
| Change in Net Operating Assets | 29.36% | 26.43% | -1,176.47% | -796.74% | -124.76% |
| Cash from Operations | 26.87% | -14.37% | -231.40% | -196.35% | -106.15% |
| Capital Expenditure | -613.04% | -310.88% | -126.70% | 11.23% | 54.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.49% | -100.49% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 319.20% | 21.53% | 76.38% | -103.69% | -116.82% |
| Cash from Investing | -87.89% | -79.77% | 1,694.60% | 340.67% | 127.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -435.28% | -435.28% | -2,933.70% | -1,033.49% | -- |
| Issuance of Common Stock | 57.24% | -34.04% | -19.59% | -23.05% | -23.19% |
| Repurchase of Common Stock | 96.90% | 98.86% | -101.39% | -89.42% | -105.77% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -- |
| Cash from Financing | -8.35% | -245.77% | -1,407.06% | -708.08% | -922.19% |
| Foreign Exchange rate Adjustments | 658.06% | -3,080.00% | -2,147.06% | -267.23% | 487.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -185.86% | -177.56% | 490.01% | 583.59% | 89.01% |